Concordia and Actavis UK stand accused of breaking UK competition law by artificially lifting the cost of hydrocortisone tablets to the National Health Service with a deal that delayed competition to the drug.
The Department of Health has introduced a new Bill in parliament that will enable the government to limit the cost of unbranded medicines in case of unreasonable price increases.